$ALTS
ALT5 Sigma Corp

2024 Q2 Form 10-Q Financial Statement

#000162828024020286 Filed on May 03, 2024

View on sec.gov

Income Statement

Concept 2024 Q2 2024 Q1 2023 Q4
Revenue $2.169M $0.00 $0.00
YoY Change -100.0%
Cost Of Revenue $1.071M $0.00 $0.00
YoY Change -100.0%
Gross Profit $1.098M $0.00 $0.00
YoY Change -100.0%
Gross Profit Margin 50.62%
Selling, General & Admin $4.014M $1.806M $1.823M
YoY Change 265.24% -36.21%
% of Gross Profit 365.57%
Research & Development
YoY Change
% of Gross Profit
Depreciation & Amortization $639.0K $362.0K
YoY Change 370.13%
% of Gross Profit
Operating Expenses $4.014M $1.806M $1.823M
YoY Change 265.24% -36.21%
Operating Profit -$2.916M -$1.806M -$1.823M
YoY Change 165.33% -0.05%
Interest Expense $4.000K -$252.0K $652.0K
YoY Change -99.16% 1711.11%
% of Operating Profit
Other Income/Expense, Net $654.0K -$413.0K -$159.0K
YoY Change 211.43% -32.05%
Pretax Income -$2.262M -$2.219M -$16.43M
YoY Change 154.44% 698.35%
Income Tax -$2.900M -$75.00K -$160.0K
% Of Pretax Income
Net Earnings $589.0K -$2.144M -$17.81M
YoY Change -94.16% 758.49%
Net Earnings / Revenue 27.16%
Basic Earnings Per Share $0.07 -$0.34
Diluted Earnings Per Share $0.07 -$0.34 -$3.59
COMMON SHARES
Basic Shares Outstanding 8.976M shares 6.308M shares 4.958M shares
Diluted Shares Outstanding 8.404M shares 6.308M shares

Balance Sheet

Concept 2024 Q2 2024 Q1 2023 Q4
SHORT-TERM ASSETS
Cash & Short-Term Investments $6.198M $241.0K $291.0K
YoY Change 1655.81% -66.47%
Cash & Equivalents $5.764M $61.00K $5.000K
Short-Term Investments $434.0K $180.0K $286.0K
Other Short-Term Assets $799.0K $75.00K
YoY Change -93.99%
Inventory
Prepaid Expenses
Receivables $865.0K $251.0K $0.00
Other Receivables $50.00K $80.00K $0.00
Total Short-Term Assets $30.90M $1.200M $346.0K
YoY Change 4750.86% -96.32%
LONG-TERM ASSETS
Property, Plant & Equipment $1.170M $0.00
YoY Change -100.0%
Goodwill $7.724M $0.00
YoY Change
Intangibles $35.00M $17.85M
YoY Change -10.91%
Long-Term Investments $180.0K $286.0K
YoY Change -4.67%
Other Assets $0.00 $0.00 $9.000K
YoY Change -100.0% -70.0%
Total Long-Term Assets $44.50M $17.38M $18.14M
YoY Change 29.58% -17.18%
TOTAL ASSETS
Total Short-Term Assets $30.90M $1.200M $346.0K
Total Long-Term Assets $44.50M $17.38M $18.14M
Total Assets $75.40M $18.58M $18.49M
YoY Change 115.56% -40.94%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable $2.937M $2.034M $2.272M
YoY Change 10.25% -62.54%
Accrued Expenses $2.541M $3.633M
YoY Change -34.83%
Deferred Revenue
YoY Change
Short-Term Debt $600.0K $0.00
YoY Change -100.0%
Long-Term Debt Due $0.00
YoY Change -100.0%
Total Short-Term Liabilities $42.50M $8.100M $5.905M
YoY Change 1114.29% -75.23%
LONG-TERM LIABILITIES
Long-Term Debt $504.0K $707.0K
YoY Change -50.39%
Other Long-Term Liabilities $0.00 $1.806M $0.00
YoY Change -100.0% -100.0%
Total Long-Term Liabilities $0.00 $1.806M $0.00
YoY Change -100.0% -100.0%
TOTAL LIABILITIES
Total Short-Term Liabilities $42.50M $8.100M $5.905M
Total Long-Term Liabilities $0.00 $1.806M $0.00
Total Liabilities $48.61M $10.95M $7.285M
YoY Change 603.87% -75.84%
SHAREHOLDERS EQUITY
Retained Earnings -$52.19M -$52.78M -$50.63M
YoY Change 59.42% 15.11%
Common Stock $59.38M $48.56M $47.33M
YoY Change 28.26% 3.44%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity $22.90M $3.800M -$3.308M
YoY Change
Total Liabilities & Shareholders Equity $75.40M $18.58M $18.49M
YoY Change 115.56% -40.94%

Cashflow Statement

Concept 2024 Q2 2024 Q1 2023 Q4
OPERATING ACTIVITIES
Net Income $589.0K -$2.144M -$17.81M
YoY Change -94.16% 758.49%
Depreciation, Depletion And Amortization $639.0K $362.0K
YoY Change 370.13%
Cash From Operating Activities -$544.0K -$409.0K
YoY Change -89.46%
INVESTING ACTIVITIES
Capital Expenditures
YoY Change
Acquisitions
YoY Change
Other Investing Activities $0.00 $1.000K
YoY Change
Cash From Investing Activities $0.00 $1.000K
YoY Change -102.5%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net $600.0K
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities $600.0K 0.000
YoY Change -100.0%
NET CHANGE
Cash From Operating Activities -$544.0K -409.0K
Cash From Investing Activities $0.00 1.000K
Cash From Financing Activities $600.0K 0.000
Net Change In Cash $56.00K -408.0K
YoY Change 30.35%
FREE CASH FLOW
Cash From Operating Activities -$544.0K -$409.0K
Capital Expenditures
Free Cash Flow
YoY Change

Facts In Submission

Frame Concept Type Concept / XBRL Key Value Unit
CY2024Q1 dei Entity Emerging Growth Company
EntityEmergingGrowthCompany
false
CY2024Q1 dei Entity Shell Company
EntityShellCompany
false
CY2024Q1 dei Current Fiscal Year End Date
CurrentFiscalYearEndDate
--12-31
CY2024Q1 dei Document Fiscal Year Focus
DocumentFiscalYearFocus
2024
CY2024Q1 dei Document Fiscal Period Focus
DocumentFiscalPeriodFocus
Q1
CY2024Q1 dei Amendment Flag
AmendmentFlag
false
CY2024Q1 dei Entity Current Reporting Status
EntityCurrentReportingStatus
Yes
CY2024Q1 dei Entity Interactive Data Current
EntityInteractiveDataCurrent
Yes
CY2024Q1 dei Entity Filer Category
EntityFilerCategory
Non-accelerated Filer
CY2024Q1 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
61000 usd
CY2024Q1 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
7551379 shares
CY2024Q1 us-gaap Marketable Securities Unrealized Gain Loss
MarketableSecuritiesUnrealizedGainLoss
-190000 usd
CY2024Q1 dei Entity Small Business
EntitySmallBusiness
true
CY2024Q2 dei Entity Common Stock Shares Outstanding
EntityCommonStockSharesOutstanding
8976379 shares
CY2024Q1 us-gaap Accounts And Other Receivables Net Current
AccountsAndOtherReceivablesNetCurrent
331000 usd
CY2024Q1 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
799000 usd
CY2023Q4 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
75000 usd
CY2024Q1 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
7551379 shares
CY2023Q2 us-gaap Marketable Securities Unrealized Gain Loss
MarketableSecuritiesUnrealizedGainLoss
-247000 usd
CY2024Q1 dei Entity Central Index Key
EntityCentralIndexKey
0000862861
CY2024Q1 us-gaap Assets Current
AssetsCurrent
1191000 usd
CY2023Q4 us-gaap Assets Current
AssetsCurrent
346000 usd
CY2024Q1 jan Finite Lived Intangible Assets Net Excluding Other Intangible Assets Net
FiniteLivedIntangibleAssetsNetExcludingOtherIntangibleAssetsNet
17203000 usd
CY2023Q4 jan Finite Lived Intangible Assets Net Excluding Other Intangible Assets Net
FiniteLivedIntangibleAssetsNetExcludingOtherIntangibleAssetsNet
17842000 usd
CY2024Q1 us-gaap Other Intangible Assets Net
OtherIntangibleAssetsNet
4000 usd
CY2023Q4 us-gaap Other Intangible Assets Net
OtherIntangibleAssetsNet
4000 usd
CY2024Q1 us-gaap Marketable Securities Noncurrent
MarketableSecuritiesNoncurrent
180000 usd
CY2023Q4 us-gaap Marketable Securities Noncurrent
MarketableSecuritiesNoncurrent
286000 usd
CY2024Q1 jan Deposits And Other Assets Noncurrent
DepositsAndOtherAssetsNoncurrent
0 usd
CY2023Q4 jan Deposits And Other Assets Noncurrent
DepositsAndOtherAssetsNoncurrent
9000 usd
CY2024Q1 us-gaap Assets
Assets
18578000 usd
CY2023Q4 us-gaap Assets
Assets
18487000 usd
CY2024Q1 us-gaap Accounts Payable Current
AccountsPayableCurrent
2034000 usd
CY2023Q4 us-gaap Accounts Payable Current
AccountsPayableCurrent
2272000 usd
CY2024Q1 us-gaap Accounts Payable And Other Accrued Liabilities Current
AccountsPayableAndOtherAccruedLiabilitiesCurrent
2541000 usd
CY2023Q4 us-gaap Accounts Payable And Other Accrued Liabilities Current
AccountsPayableAndOtherAccruedLiabilitiesCurrent
3633000 usd
CY2024Q1 us-gaap Other Liabilities Current
OtherLiabilitiesCurrent
2900000 usd
CY2023Q4 us-gaap Other Liabilities Current
OtherLiabilitiesCurrent
0 usd
CY2024Q1 us-gaap Liabilities Current
LiabilitiesCurrent
8075000 usd
CY2023Q4 us-gaap Liabilities Current
LiabilitiesCurrent
5905000 usd
CY2024Q1 us-gaap Deferred Income Tax Liabilities Net
DeferredIncomeTaxLiabilitiesNet
564000 usd
CY2023Q4 us-gaap Deferred Income Tax Liabilities Net
DeferredIncomeTaxLiabilitiesNet
639000 usd
CY2024Q1 us-gaap Other Liabilities Noncurrent
OtherLiabilitiesNoncurrent
1806000 usd
CY2023Q4 us-gaap Other Liabilities Noncurrent
OtherLiabilitiesNoncurrent
0 usd
CY2024Q1 us-gaap Liabilities Of Disposal Group Including Discontinued Operation Noncurrent
LiabilitiesOfDisposalGroupIncludingDiscontinuedOperationNoncurrent
0 usd
CY2023Q4 us-gaap Liabilities Of Disposal Group Including Discontinued Operation Noncurrent
LiabilitiesOfDisposalGroupIncludingDiscontinuedOperationNoncurrent
34000 usd
CY2024Q1 us-gaap Liabilities
Liabilities
10949000 usd
CY2023Q4 us-gaap Liabilities
Liabilities
7285000 usd
CY2024Q1 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
usd
CY2023Q4 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
usd
CY2024Q1 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.001
CY2023Q4 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.001
CY2023Q4 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
200000000 shares
CY2024Q1 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
200000000 shares
CY2023Q4 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
4957647 shares
CY2023Q4 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
4957647 shares
CY2024Q1 us-gaap Common Stock Value
CommonStockValue
5000 usd
CY2023Q4 us-gaap Common Stock Value
CommonStockValue
3000 usd
CY2024Q1 us-gaap Additional Paid In Capital Common Stock
AdditionalPaidInCapitalCommonStock
48553000 usd
CY2023Q4 us-gaap Additional Paid In Capital Common Stock
AdditionalPaidInCapitalCommonStock
47323000 usd
CY2024Q1 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-52778000 usd
CY2023Q4 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-50634000 usd
CY2024Q1 us-gaap Stockholders Equity
StockholdersEquity
3773000 usd
CY2023Q4 us-gaap Stockholders Equity
StockholdersEquity
-3308000 usd
CY2024Q1 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
18578000 usd
CY2023Q4 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
18487000 usd
CY2024Q1 us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
0 usd
CY2023Q2 us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
0 usd
CY2024Q1 us-gaap Cost Of Revenue
CostOfRevenue
0 usd
CY2023Q2 us-gaap Cost Of Revenue
CostOfRevenue
0 usd
CY2024Q1 us-gaap Gross Profit
GrossProfit
0 usd
CY2023Q2 us-gaap Gross Profit
GrossProfit
0 usd
CY2024Q1 us-gaap Selling General And Administrative Expense
SellingGeneralAndAdministrativeExpense
1806000 usd
CY2023Q2 us-gaap Selling General And Administrative Expense
SellingGeneralAndAdministrativeExpense
1099000 usd
CY2024Q1 us-gaap Operating Income Loss
OperatingIncomeLoss
-1806000 usd
CY2023Q2 us-gaap Operating Income Loss
OperatingIncomeLoss
-1099000 usd
CY2024Q1 us-gaap Interest Income Expense Net
InterestIncomeExpenseNet
-252000 usd
CY2023Q2 us-gaap Interest Income Expense Net
InterestIncomeExpenseNet
475000 usd
CY2024Q1 us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
29000 usd
CY2023Q2 us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
-18000 usd
CY2024Q1 us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
-413000 usd
CY2023Q2 us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
210000 usd
CY2024Q1 us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
-2219000 usd
CY2023Q2 us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
-889000 usd
CY2024Q1 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
-75000 usd
CY2023Q2 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
-227000 usd
CY2024Q1 us-gaap Income Loss From Continuing Operations
IncomeLossFromContinuingOperations
-2144000 usd
CY2023Q2 us-gaap Income Loss From Continuing Operations
IncomeLossFromContinuingOperations
-662000 usd
CY2023Q2 us-gaap Gain Loss On Disposition Of Real Estate Discontinued Operations
GainLossOnDispositionOfRealEstateDiscontinuedOperations
15800000 usd
CY2024Q1 us-gaap Discontinued Operation Gain Loss From Disposal Of Discontinued Operation Before Income Tax
DiscontinuedOperationGainLossFromDisposalOfDiscontinuedOperationBeforeIncomeTax
0 usd
CY2023Q2 us-gaap Discontinued Operation Gain Loss From Disposal Of Discontinued Operation Before Income Tax
DiscontinuedOperationGainLossFromDisposalOfDiscontinuedOperationBeforeIncomeTax
13976000 usd
CY2024Q1 us-gaap Discontinued Operation Tax Effect Of Income Loss From Disposal Of Discontinued Operation
DiscontinuedOperationTaxEffectOfIncomeLossFromDisposalOfDiscontinuedOperation
0 usd
CY2023Q2 us-gaap Discontinued Operation Tax Effect Of Income Loss From Disposal Of Discontinued Operation
DiscontinuedOperationTaxEffectOfIncomeLossFromDisposalOfDiscontinuedOperation
3229000 usd
CY2024Q1 us-gaap Income Loss From Discontinued Operations Net Of Tax Attributable To Reporting Entity
IncomeLossFromDiscontinuedOperationsNetOfTaxAttributableToReportingEntity
0 usd
CY2023Q2 us-gaap Income Loss From Discontinued Operations Net Of Tax Attributable To Reporting Entity
IncomeLossFromDiscontinuedOperationsNetOfTaxAttributableToReportingEntity
10747000 usd
CY2024Q1 us-gaap Net Income Loss
NetIncomeLoss
-2144000 usd
CY2023Q2 us-gaap Net Income Loss
NetIncomeLoss
10085000 usd
CY2024Q1 us-gaap Income Loss From Continuing Operations Per Diluted Share
IncomeLossFromContinuingOperationsPerDilutedShare
-0.34
CY2024Q1 us-gaap Income Loss From Continuing Operations Per Basic Share
IncomeLossFromContinuingOperationsPerBasicShare
-0.34
CY2023Q2 us-gaap Income Loss From Continuing Operations Per Diluted Share
IncomeLossFromContinuingOperationsPerDilutedShare
-0.21
CY2023Q2 us-gaap Income Loss From Continuing Operations Per Basic Share
IncomeLossFromContinuingOperationsPerBasicShare
-0.21
CY2024Q1 us-gaap Discontinued Operation Income Loss From Discontinued Operation Net Of Tax Per Diluted Share
DiscontinuedOperationIncomeLossFromDiscontinuedOperationNetOfTaxPerDilutedShare
0
CY2024Q1 us-gaap Discontinued Operation Income Loss From Discontinued Operation Net Of Tax Per Basic Share
DiscontinuedOperationIncomeLossFromDiscontinuedOperationNetOfTaxPerBasicShare
0
CY2023Q2 us-gaap Discontinued Operation Income Loss From Discontinued Operation Net Of Tax Per Diluted Share
DiscontinuedOperationIncomeLossFromDiscontinuedOperationNetOfTaxPerDilutedShare
3.36
CY2023Q2 us-gaap Discontinued Operation Income Loss From Discontinued Operation Net Of Tax Per Basic Share
DiscontinuedOperationIncomeLossFromDiscontinuedOperationNetOfTaxPerBasicShare
3.36
CY2024Q1 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.34
CY2024Q1 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.34
CY2023Q2 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
3.15
CY2023Q2 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
3.15
CY2024Q1 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
6308331 shares
CY2023Q2 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
3199061 shares
CY2024Q1 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
6308331 shares
CY2023Q2 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
3199061 shares
CY2024Q1 us-gaap Income Loss From Continuing Operations
IncomeLossFromContinuingOperations
-2144000 usd
CY2023Q2 us-gaap Income Loss From Continuing Operations
IncomeLossFromContinuingOperations
-662000 usd
CY2024Q1 us-gaap Depreciation Depletion And Amortization
DepreciationDepletionAndAmortization
639000 usd
CY2023Q2 us-gaap Depreciation Depletion And Amortization
DepreciationDepletionAndAmortization
364000 usd
CY2024Q1 us-gaap Share Based Compensation
ShareBasedCompensation
345000 usd
CY2023Q2 us-gaap Share Based Compensation
ShareBasedCompensation
8000 usd
CY2024Q1 us-gaap Financial Guarantee Insurance Contracts Premiums Receivable Accretion Of Discount On Premium Receivable
FinancialGuaranteeInsuranceContractsPremiumsReceivableAccretionOfDiscountOnPremiumReceivable
0 usd
CY2023Q2 us-gaap Financial Guarantee Insurance Contracts Premiums Receivable Accretion Of Discount On Premium Receivable
FinancialGuaranteeInsuranceContractsPremiumsReceivableAccretionOfDiscountOnPremiumReceivable
230000 usd
CY2024Q1 us-gaap Marketable Securities Unrealized Gain Loss
MarketableSecuritiesUnrealizedGainLoss
-190000 usd
CY2023Q2 us-gaap Marketable Securities Unrealized Gain Loss
MarketableSecuritiesUnrealizedGainLoss
-247000 usd
CY2024Q1 us-gaap Increase Decrease In Notes Receivable Related Parties
IncreaseDecreaseInNotesReceivableRelatedParties
-600000 usd
CY2023Q2 us-gaap Increase Decrease In Notes Receivable Related Parties
IncreaseDecreaseInNotesReceivableRelatedParties
0 usd
CY2024Q1 us-gaap Increase Decrease In Deferred Income Taxes
IncreaseDecreaseInDeferredIncomeTaxes
75000 usd
CY2023Q2 us-gaap Increase Decrease In Deferred Income Taxes
IncreaseDecreaseInDeferredIncomeTaxes
0 usd
CY2024Q1 us-gaap Increase Decrease In Accounts Receivable
IncreaseDecreaseInAccountsReceivable
149000 usd
CY2023Q2 us-gaap Increase Decrease In Accounts Receivable
IncreaseDecreaseInAccountsReceivable
3000 usd
CY2024Q1 us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
-7000 usd
CY2023Q2 us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
-125000 usd
CY2024Q1 us-gaap Increase Decrease In Accounts Payable And Accrued Liabilities
IncreaseDecreaseInAccountsPayableAndAccruedLiabilities
33000 usd
CY2023Q2 us-gaap Increase Decrease In Accounts Payable And Accrued Liabilities
IncreaseDecreaseInAccountsPayableAndAccruedLiabilities
256000 usd
CY2024Q1 us-gaap Increase Decrease In Other Operating Assets
IncreaseDecreaseInOtherOperatingAssets
-10000 usd
CY2023Q2 us-gaap Increase Decrease In Other Operating Assets
IncreaseDecreaseInOtherOperatingAssets
-1000 usd
CY2024Q1 us-gaap Cash Provided By Used In Operating Activities Discontinued Operations
CashProvidedByUsedInOperatingActivitiesDiscontinuedOperations
0 usd
CY2023Q2 us-gaap Cash Provided By Used In Operating Activities Discontinued Operations
CashProvidedByUsedInOperatingActivitiesDiscontinuedOperations
2320000 usd
CY2024Q1 us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-544000 usd
CY2023Q2 us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
2426000 usd
CY2024Q1 us-gaap Cash Provided By Used In Investing Activities Discontinued Operations
CashProvidedByUsedInInvestingActivitiesDiscontinuedOperations
0 usd
CY2023Q2 us-gaap Cash Provided By Used In Investing Activities Discontinued Operations
CashProvidedByUsedInInvestingActivitiesDiscontinuedOperations
-156000 usd
CY2024Q1 us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
0 usd
CY2023Q2 us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
-156000 usd
CY2024Q1 us-gaap Proceeds From Issuance Of Common Stock
ProceedsFromIssuanceOfCommonStock
600000 usd
CY2023Q2 us-gaap Proceeds From Issuance Of Common Stock
ProceedsFromIssuanceOfCommonStock
368000 usd
CY2024Q1 us-gaap Repayments Of Notes Payable
RepaymentsOfNotesPayable
0 usd
CY2023Q2 us-gaap Repayments Of Notes Payable
RepaymentsOfNotesPayable
205000 usd
CY2024Q1 us-gaap Cash Provided By Used In Financing Activities Discontinued Operations
CashProvidedByUsedInFinancingActivitiesDiscontinuedOperations
0 usd
CY2023Q2 us-gaap Cash Provided By Used In Financing Activities Discontinued Operations
CashProvidedByUsedInFinancingActivitiesDiscontinuedOperations
-2212000 usd
CY2024Q1 us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
600000 usd
CY2023Q2 us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
-2049000 usd
CY2024Q1 us-gaap Effect Of Exchange Rate On Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
0 usd
CY2023Q2 us-gaap Effect Of Exchange Rate On Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
17000 usd
CY2024Q1 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
56000 usd
CY2023Q2 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
238000 usd
CY2023Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
5000 usd
CY2022Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
115000 usd
CY2024Q1 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Disposal Group Including Discontinued Operations
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsDisposalGroupIncludingDiscontinuedOperations
0 usd
CY2023Q2 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Disposal Group Including Discontinued Operations
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsDisposalGroupIncludingDiscontinuedOperations
0 usd
CY2024Q1 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
61000 usd
CY2023Q2 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
353000 usd
CY2024Q1 us-gaap Interest Paid Net
InterestPaidNet
0 usd
CY2023Q2 us-gaap Interest Paid Net
InterestPaidNet
117000 usd
CY2023Q4 us-gaap Stockholders Equity
StockholdersEquity
-3308000 usd
CY2024Q1 us-gaap Stock Issued During Period Value Share Based Compensation
StockIssuedDuringPeriodValueShareBasedCompensation
345000 usd
CY2024Q1 jan Adjustment To Additional Paid In Capital Reclassifications Of Temporary To Liability
AdjustmentToAdditionalPaidInCapitalReclassificationsOfTemporaryToLiability
339000 usd
CY2024Q1 us-gaap Reclassifications Of Temporary To Permanent Equity
ReclassificationsOfTemporaryToPermanentEquity
7993000 usd
CY2024Q1 us-gaap Stock Issued During Period Value New Issues
StockIssuedDuringPeriodValueNewIssues
627000 usd
CY2024Q1 jan Common Stock Issued For Consulting Agreement Value
CommonStockIssuedForConsultingAgreementValue
232000 usd
CY2024Q1 us-gaap Stock Issued During Period Value Issued For Services
StockIssuedDuringPeriodValueIssuedForServices
367000 usd
CY2024Q1 us-gaap Profit Loss
ProfitLoss
-2144000 usd
CY2024Q1 us-gaap Stockholders Equity
StockholdersEquity
3773000 usd
CY2022Q4 us-gaap Stockholders Equity
StockholdersEquity
2307000 usd
CY2023Q2 us-gaap Stock Issued During Period Value Share Based Compensation
StockIssuedDuringPeriodValueShareBasedCompensation
8000 usd
CY2023Q2 us-gaap Stock Issued During Period Value New Issues
StockIssuedDuringPeriodValueNewIssues
369000 usd
CY2023Q2 jan Common Stock Issued For Legal Settlement Value
CommonStockIssuedForLegalSettlementValue
170000 usd
CY2023Q2 us-gaap Other Comprehensive Income Loss Net Of Tax
OtherComprehensiveIncomeLossNetOfTax
621000 usd
CY2023Q2 us-gaap Profit Loss
ProfitLoss
10085000 usd
CY2023Q2 us-gaap Stockholders Equity
StockholdersEquity
13560000 usd
CY2024Q1 us-gaap Number Of Operating Segments
NumberOfOperatingSegments
2 segment
CY2024Q1 jan Potential Market Exclusivity Period
PotentialMarketExclusivityPeriod
P7Y
CY2024Q1 us-gaap Income Loss From Continuing Operations
IncomeLossFromContinuingOperations
-2100000 usd
CY2024Q1 us-gaap Assets Current
AssetsCurrent
1200000 usd
CY2024Q1 us-gaap Liabilities Current
LiabilitiesCurrent
8100000 usd
CY2024Q1 jan Current Assets Current Liabilities Net
CurrentAssetsCurrentLiabilitiesNet
-6900000 usd
CY2024Q1 us-gaap Net Cash Provided By Used In Continuing Operations
NetCashProvidedByUsedInContinuingOperations
-544000 usd
CY2024Q1 us-gaap Stockholders Equity
StockholdersEquity
3800000 usd
CY2024Q1 us-gaap Use Of Estimates
UseOfEstimates
<div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Use of Estimates</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The preparation of the consolidated financial statements in conformity with U.S. GAAP requires management to make estimates and assumption that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the consolidated financial statements and the reported amounts of revenues and expenses during the reporting period. Actual results could differ from those estimates.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Significant estimates made in connection with the accompanying consolidated financial statements include the fair value in connection with the Series S convertible preferred stock issued in the Soin merger, valuation allowance against deferred tax assets, and estimated useful lives for intangible assets.</span></div>
CY2024Q1 us-gaap Interest Receivable Current
InterestReceivableCurrent
251000 usd
CY2023Q4 us-gaap Interest Receivable Current
InterestReceivableCurrent
266000 usd
CY2024Q1 us-gaap Other Receivables Net Current
OtherReceivablesNetCurrent
80000 usd
CY2023Q4 us-gaap Other Receivables Net Current
OtherReceivablesNetCurrent
0 usd
CY2024Q1 us-gaap Accounts And Other Receivables Net Current
AccountsAndOtherReceivablesNetCurrent
331000 usd
CY2023Q4 us-gaap Accounts And Other Receivables Net Current
AccountsAndOtherReceivablesNetCurrent
266000 usd
CY2024Q1 us-gaap Net Income Loss From Continuing Operations Available To Common Shareholders Diluted
NetIncomeLossFromContinuingOperationsAvailableToCommonShareholdersDiluted
-2144000 usd
CY2024Q1 us-gaap Net Income Loss From Continuing Operations Available To Common Shareholders Basic
NetIncomeLossFromContinuingOperationsAvailableToCommonShareholdersBasic
-2144000 usd
CY2024Q1 jan Prepaid Consulting Agreement
PrepaidConsultingAgreement
732000 usd
CY2023Q4 jan Prepaid Consulting Agreement
PrepaidConsultingAgreement
3000 usd
CY2024Q1 us-gaap Prepaid Insurance
PrepaidInsurance
2000 usd
CY2023Q4 us-gaap Prepaid Insurance
PrepaidInsurance
72000 usd
CY2024Q1 us-gaap Other Prepaid Expense Current
OtherPrepaidExpenseCurrent
65000 usd
CY2023Q4 us-gaap Other Prepaid Expense Current
OtherPrepaidExpenseCurrent
0 usd
CY2024Q1 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
799000 usd
CY2023Q4 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
75000 usd
CY2023Q4 jan Number Of Pending Patents
NumberOfPendingPatents
2 patent
CY2024Q1 jan Number Of Pending Patents
NumberOfPendingPatents
2 patent
CY2023Q4 jan Number Of Approved Patents
NumberOfApprovedPatents
1 patent
CY2024Q1 jan Number Of Approved Patents
NumberOfApprovedPatents
1 patent
CY2024Q1 us-gaap Amortization Of Intangible Assets
AmortizationOfIntangibleAssets
639000 usd
CY2023Q2 us-gaap Amortization Of Intangible Assets
AmortizationOfIntangibleAssets
363000 usd
CY2023Q4 us-gaap Marketable Securities
MarketableSecurities
286000 usd
CY2024Q1 us-gaap Proceeds From Sale And Maturity Of Marketable Securities
ProceedsFromSaleAndMaturityOfMarketableSecurities
84000 usd
CY2024Q1 us-gaap Marketable Securities Unrealized Gain Loss
MarketableSecuritiesUnrealizedGainLoss
-190000 usd
CY2024Q1 us-gaap Marketable Securities
MarketableSecurities
180000 usd
CY2024Q1 us-gaap Employee Related Liabilities Current
EmployeeRelatedLiabilitiesCurrent
58000 usd
CY2023Q4 us-gaap Employee Related Liabilities Current
EmployeeRelatedLiabilitiesCurrent
37000 usd
CY2024Q1 jan Accrued Guarantees Current
AccruedGuaranteesCurrent
1983000 usd
CY2023Q4 jan Accrued Guarantees Current
AccruedGuaranteesCurrent
3049000 usd
CY2024Q1 us-gaap Accrued Income Taxes Current
AccruedIncomeTaxesCurrent
103000 usd
CY2023Q4 us-gaap Accrued Income Taxes Current
AccruedIncomeTaxesCurrent
102000 usd
CY2024Q1 us-gaap Litigation Reserve Current
LitigationReserveCurrent
397000 usd
CY2023Q4 us-gaap Litigation Reserve Current
LitigationReserveCurrent
397000 usd
CY2024Q1 us-gaap Accounts Payable Other Current
AccountsPayableOtherCurrent
0 usd
CY2023Q4 us-gaap Accounts Payable Other Current
AccountsPayableOtherCurrent
48000 usd
CY2024Q1 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
2541000 usd
CY2023Q4 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
3633000 usd
CY2024Q1 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
7551379 shares
CY2024Q1 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
7551379 shares
CY2023Q4 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
4957647 shares
CY2023Q4 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
4957647 shares
CY2023Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
114000 shares
CY2023Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
5.68
CY2023Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue
0 usd
CY2023 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2
P6Y1M6D
CY2024Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
114000 shares
CY2024Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
5.68
CY2024Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue
11000 usd
CY2024Q1 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2
P5Y10M24D
CY2024Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber
114000 shares
CY2024Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice
5.68
CY2024Q1 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Intrinsic Value1
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1
11000 usd
CY2024Q1 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Weighted Average Remaining Contractual Term1
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1
P5Y10M24D
CY2024Q1 jan Reclassifications Of Temporary To Current Liability
ReclassificationsOfTemporaryToCurrentLiability
2700000 usd
CY2024Q1 us-gaap Reclassifications Of Temporary To Permanent Equity
ReclassificationsOfTemporaryToPermanentEquity
8000000 usd
CY2024Q1 us-gaap Temporary Equity Carrying Amount Attributable To Parent
TemporaryEquityCarryingAmountAttributableToParent
3900000 usd
CY2023Q2 us-gaap Net Income Loss From Continuing Operations Available To Common Shareholders Basic
NetIncomeLossFromContinuingOperationsAvailableToCommonShareholdersBasic
-662000 usd
CY2023Q2 us-gaap Net Income Loss From Continuing Operations Available To Common Shareholders Diluted
NetIncomeLossFromContinuingOperationsAvailableToCommonShareholdersDiluted
-662000 usd
CY2024Q1 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
6308331 shares
CY2024Q1 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
6308331 shares
CY2023Q2 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
3199061 shares
CY2023Q2 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
3199061 shares
CY2024Q1 us-gaap Income Loss From Continuing Operations Per Basic Share
IncomeLossFromContinuingOperationsPerBasicShare
-0.34
CY2024Q1 us-gaap Income Loss From Continuing Operations Per Diluted Share
IncomeLossFromContinuingOperationsPerDilutedShare
-0.34
CY2023Q2 us-gaap Income Loss From Continuing Operations Per Basic Share
IncomeLossFromContinuingOperationsPerBasicShare
-0.21
CY2023Q2 us-gaap Income Loss From Continuing Operations Per Diluted Share
IncomeLossFromContinuingOperationsPerDilutedShare
-0.21
CY2024Q1 us-gaap Net Income Loss From Discontinued Operations Available To Common Shareholders Basic
NetIncomeLossFromDiscontinuedOperationsAvailableToCommonShareholdersBasic
0 usd
CY2024Q1 us-gaap Net Income Loss From Discontinued Operations Available To Common Shareholders Diluted
NetIncomeLossFromDiscontinuedOperationsAvailableToCommonShareholdersDiluted
0 usd
CY2023Q2 us-gaap Net Income Loss From Discontinued Operations Available To Common Shareholders Basic
NetIncomeLossFromDiscontinuedOperationsAvailableToCommonShareholdersBasic
10747000 usd
CY2023Q2 us-gaap Net Income Loss From Discontinued Operations Available To Common Shareholders Diluted
NetIncomeLossFromDiscontinuedOperationsAvailableToCommonShareholdersDiluted
10747000 usd
CY2024Q1 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
6308331 shares
CY2024Q1 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
6308331 shares
CY2023Q2 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
3199061 shares
CY2023Q2 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
3199061 shares
CY2024Q1 us-gaap Discontinued Operation Income Loss From Discontinued Operation Net Of Tax Per Basic Share
DiscontinuedOperationIncomeLossFromDiscontinuedOperationNetOfTaxPerBasicShare
0
CY2024Q1 us-gaap Discontinued Operation Income Loss From Discontinued Operation Net Of Tax Per Diluted Share
DiscontinuedOperationIncomeLossFromDiscontinuedOperationNetOfTaxPerDilutedShare
0
CY2023Q2 us-gaap Discontinued Operation Income Loss From Discontinued Operation Net Of Tax Per Basic Share
DiscontinuedOperationIncomeLossFromDiscontinuedOperationNetOfTaxPerBasicShare
3.36
CY2023Q2 us-gaap Discontinued Operation Income Loss From Discontinued Operation Net Of Tax Per Diluted Share
DiscontinuedOperationIncomeLossFromDiscontinuedOperationNetOfTaxPerDilutedShare
3.36
CY2024Q1 us-gaap Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
-2144000 usd
CY2024Q1 us-gaap Net Income Loss Available To Common Stockholders Diluted
NetIncomeLossAvailableToCommonStockholdersDiluted
-2144000 usd
CY2023Q2 us-gaap Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
10085000 usd
CY2023Q2 us-gaap Net Income Loss Available To Common Stockholders Diluted
NetIncomeLossAvailableToCommonStockholdersDiluted
10085000 usd
CY2024Q1 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
6308331 shares
CY2024Q1 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
6308331 shares
CY2023Q2 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
3199061 shares
CY2023Q2 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
3199061 shares
CY2024Q1 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.34
CY2024Q1 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.34
CY2023Q2 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
3.15
CY2023Q2 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
3.15
CY2024Q1 us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
114000 shares
CY2023Q2 us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
120000 shares
CY2024Q1 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
-75000 usd
CY2023Q2 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
-227000 usd
CY2024Q1 us-gaap Effective Income Tax Rate Continuing Operations
EffectiveIncomeTaxRateContinuingOperations
0.034
CY2023Q2 us-gaap Effective Income Tax Rate Continuing Operations
EffectiveIncomeTaxRateContinuingOperations
0.229
CY2024Q1 us-gaap Number Of Reportable Segments
NumberOfReportableSegments
2 segment

Files In Submission

Name View Source Status
0001628280-24-020286-index-headers.html Edgar Link pending
0001628280-24-020286-index.html Edgar Link pending
0001628280-24-020286.txt Edgar Link pending
0001628280-24-020286-xbrl.zip Edgar Link pending
Financial_Report.xlsx Edgar Link pending
jan-20240330.htm Edgar Link pending
jan-20240330.xsd Edgar Link pending
jan-20240330xexx311.htm Edgar Link pending
jan-20240330xexx312.htm Edgar Link pending
jan-20240330xexx321.htm Edgar Link pending
jan-20240330xexx322.htm Edgar Link pending
MetaLinks.json Edgar Link pending
R1.htm Edgar Link pending
R10.htm Edgar Link pending
R11.htm Edgar Link pending
R12.htm Edgar Link pending
R13.htm Edgar Link pending
R14.htm Edgar Link pending
R15.htm Edgar Link pending
R16.htm Edgar Link pending
R17.htm Edgar Link pending
R18.htm Edgar Link pending
FilingSummary.xml Edgar Link unprocessable
jan-20240330_cal.xml Edgar Link unprocessable
jan-20240330_def.xml Edgar Link unprocessable
jan-20240330_lab.xml Edgar Link unprocessable
jan-20240330_pre.xml Edgar Link unprocessable
jan-20240330_htm.xml Edgar Link completed
R19.htm Edgar Link pending
R2.htm Edgar Link pending
R20.htm Edgar Link pending
R21.htm Edgar Link pending
R22.htm Edgar Link pending
R23.htm Edgar Link pending
R24.htm Edgar Link pending
R25.htm Edgar Link pending
R26.htm Edgar Link pending
R27.htm Edgar Link pending
R28.htm Edgar Link pending
R29.htm Edgar Link pending
R3.htm Edgar Link pending
R30.htm Edgar Link pending
R31.htm Edgar Link pending
R32.htm Edgar Link pending
R33.htm Edgar Link pending
R34.htm Edgar Link pending
R35.htm Edgar Link pending
R36.htm Edgar Link pending
R37.htm Edgar Link pending
R38.htm Edgar Link pending
R39.htm Edgar Link pending
R4.htm Edgar Link pending
R40.htm Edgar Link pending
R41.htm Edgar Link pending
R42.htm Edgar Link pending
R43.htm Edgar Link pending
R44.htm Edgar Link pending
R45.htm Edgar Link pending
R46.htm Edgar Link pending
R47.htm Edgar Link pending
R48.htm Edgar Link pending
R49.htm Edgar Link pending
R5.htm Edgar Link pending
R50.htm Edgar Link pending
R51.htm Edgar Link pending
R52.htm Edgar Link pending
R53.htm Edgar Link pending
R54.htm Edgar Link pending
R55.htm Edgar Link pending
R56.htm Edgar Link pending
R57.htm Edgar Link pending
R58.htm Edgar Link pending
R6.htm Edgar Link pending
R7.htm Edgar Link pending
R8.htm Edgar Link pending
R9.htm Edgar Link pending
report.css Edgar Link pending
Show.js Edgar Link pending